7M6F
 
 | |
7M6G
 | |
7M6I
 | |
7M6E
 | |
7M6H
 | |
7M6D
 | |
8D47
 | |
8D48
 | | sd1.040 Fab in complex with SARS-CoV-2 Spike 2P glycoprotein | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Spike glycoprotein, sd1.040 Fab heavy chain, ... | | Authors: | Abernathy, M.E, Barnes, C.O. | | Deposit date: | 2022-06-01 | | Release date: | 2023-01-25 | | Last modified: | 2023-03-22 | | Method: | ELECTRON MICROSCOPY (3.7 Å) | | Cite: | Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein.
Sci Immunol, 8, 2023
|
|
6UDK
 | | HIV-1 bNAb 1-55 in complex with modified BG505 SOSIP-based immunogen RC1 and 10-1074 | | Descriptor: | 1-55 Fab Heavy Chain, 1-55 Fab Light Chain, 10-1074 Fab Heavy Chain, ... | | Authors: | Abernathy, M.E, Barnes, C.O, Gristick, H.B, Bjorkman, P.J. | | Deposit date: | 2019-09-19 | | Release date: | 2020-01-29 | | Last modified: | 2020-07-29 | | Method: | ELECTRON MICROSCOPY (3.9 Å) | | Cite: | Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody.
Cell, 180, 2020
|
|
6UDJ
 | | HIV-1 bNAb 1-18 in complex with BG505 SOSIP.664 and 10-1074 | | Descriptor: | 1-18 Fab Heavy Chain, 1-18 Fab Light Chain, 10-1074 Fab Heavy Chain, ... | | Authors: | Abernathy, M.E, Barnes, C.O, Gristick, H.B, Bjorkman, P.J. | | Deposit date: | 2019-09-19 | | Release date: | 2020-01-29 | | Last modified: | 2020-07-29 | | Method: | ELECTRON MICROSCOPY (2.5 Å) | | Cite: | Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody.
Cell, 180, 2020
|
|
7R8O
 | | Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C548 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, ... | | Authors: | DeLaitsch, A.T, Barnes, C.O, Bjorkman, P.J. | | Deposit date: | 2021-06-26 | | Release date: | 2021-08-04 | | Last modified: | 2021-10-13 | | Method: | ELECTRON MICROSCOPY (3.5 Å) | | Cite: | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.
Immunity, 54, 2021
|
|
7R8M
 | | Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C032 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, ... | | Authors: | DeLaitsch, A.T, Barnes, C.O, Bjorkman, P.J. | | Deposit date: | 2021-06-26 | | Release date: | 2021-08-04 | | Last modified: | 2021-10-06 | | Method: | ELECTRON MICROSCOPY (3.4 Å) | | Cite: | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.
Immunity, 54, 2021
|
|
7S0B
 | | Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody N-612-056 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, N-612-056 Fab Heavy Chain, N-612-056 Light Chain, ... | | Authors: | Tanaka, S, Barnes, C.O, Bjorkman, P.J. | | Deposit date: | 2021-08-30 | | Release date: | 2021-10-06 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (2.9 Å) | | Cite: | Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display.
Cell Rep, 38, 2022
|
|
7N3E
 | | Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment C032 | | Descriptor: | C032 Fab Heavy Chain, C032 Fab Light Chain | | Authors: | Flyak, A.I, Bjorkman, P.J, Barnes, C.O. | | Deposit date: | 2021-06-01 | | Release date: | 2021-08-04 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (2.06 Å) | | Cite: | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.
Immunity, 54, 2021
|
|
7N3G
 | | Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment C098 | | Descriptor: | C098 Fab Heavy Chain, C098 Fab Light Chain | | Authors: | Flyak, A.I, Bjorkman, P.J, Barnes, C.O. | | Deposit date: | 2021-06-01 | | Release date: | 2021-08-04 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (1.42 Å) | | Cite: | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.
Immunity, 54, 2021
|
|
7N3F
 | | Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment C080 | | Descriptor: | C080 Fab Heavy Chain, C080 Fab Light Chain | | Authors: | Flyak, A.I, Bjorkman, P.J, Barnes, C.O. | | Deposit date: | 2021-06-01 | | Release date: | 2021-08-04 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (1.9 Å) | | Cite: | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.
Immunity, 54, 2021
|
|
7N3I
 | | Crystal structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody Fab fragment C098 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, C098 Fab heavy chain, C098 Fab light chain, ... | | Authors: | Flyak, A.I, Bjorkman, P.J, Barnes, C.O. | | Deposit date: | 2021-06-01 | | Release date: | 2021-08-04 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (2.03 Å) | | Cite: | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.
Immunity, 54, 2021
|
|
7N3H
 | | Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment C099 | | Descriptor: | C099 Fab Heavy Chain, C099 Fab Light Chain | | Authors: | Flyak, A.I, Bjorkman, P.J, Barnes, C.O. | | Deposit date: | 2021-06-01 | | Release date: | 2021-08-04 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (1.26 Å) | | Cite: | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.
Immunity, 54, 2021
|
|
7UGM
 | |
7RKS
 | | Structure of the SARS-CoV receptor binding domain in complex with the human neutralizing antibody Fab fragment, C118 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, C118 Antibody Fab Heavy Chain, ... | | Authors: | Jette, C.A, Bjorkman, P.J, Barnes, C.O. | | Deposit date: | 2021-07-22 | | Release date: | 2021-09-22 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.
Cell Rep, 36, 2021
|
|
7RKU
 | | Structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody Fab fragment, C022 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, C022 Antibody Fab Heavy Chain, C022 Antibody Fab Light Chain, ... | | Authors: | Jette, C.A, Bjorkman, P.J, Barnes, C.O. | | Deposit date: | 2021-07-22 | | Release date: | 2021-09-22 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (3.2 Å) | | Cite: | Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.
Cell Rep, 36, 2021
|
|
5JK7
 | | The X-ray structure of the DDB1-DCAF1-Vpr-UNG2 complex | | Descriptor: | DNA damage-binding protein 1, Protein VPRBP, Protein Vpr, ... | | Authors: | Calero, G, Ahn, J, Wu, Y. | | Deposit date: | 2016-04-26 | | Release date: | 2016-10-05 | | Last modified: | 2024-03-06 | | Method: | X-RAY DIFFRACTION (3.49 Å) | | Cite: | The DDB1-DCAF1-Vpr-UNG2 crystal structure reveals how HIV-1 Vpr steers human UNG2 toward destruction.
Nat.Struct.Mol.Biol., 23, 2016
|
|
5TX2
 | | Miniature TGF-beta2 3-mutant monomer | | Descriptor: | Transforming growth factor beta-2 | | Authors: | Taylor, A.B, Kim, S.K, Hart, P.J, Hinck, A.P. | | Deposit date: | 2016-11-15 | | Release date: | 2017-03-01 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (1.82 Å) | | Cite: | An engineered transforming growth factor beta (TGF-beta ) monomer that functions as a dominant negative to block TGF-beta signaling.
J. Biol. Chem., 292, 2017
|
|
5TX4
 | | Derivative of mouse TGF-beta2, with a deletion of residues 52-71 and K25R, R26K, L51R, A74K, C77S, L89V, I92V, K94R T95K, I98V single amino acid substitutions, bound to human TGF-beta type II receptor ectodomain residues 15-130 | | Descriptor: | TGF-beta receptor type-2, Transforming growth factor beta-2 | | Authors: | Hinck, A.P, Kim, S. | | Deposit date: | 2016-11-15 | | Release date: | 2017-03-01 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (1.876 Å) | | Cite: | An engineered transforming growth factor beta (TGF-beta ) monomer that functions as a dominant negative to block TGF-beta signaling.
J. Biol. Chem., 292, 2017
|
|
5TX6
 | |
